SPI 256

Drug Profile

SPI 256

Alternative Names: SPI-256

Latest Information Update: 11 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sequoia Pharmaceuticals
  • Class Antiretrovirals; Antivirals
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 29 Oct 2008 Final pharmacokinetic and adverse events data from a phase I trial in HIV infections presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,.
  • 30 Jun 2007 Phase-I clinical trials in HIV infections in USA (unspecified route)
  • 28 Feb 2007 Sequoia Pharmaceuticals files an IND with the the US FDA for SPI 256
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top